| April Marie Rohrer, FNP-C | |
|
3000 32nd Ave S, Fargo, ND 58103-6132 | |
| (701) 364-4354 | |
| Not Available |
| Full Name | April Marie Rohrer |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 3000 32nd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073385365 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R40514 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| April Marie Rohrer, FNP-C 3000 32nd Ave S, Fargo, ND 58103-6132 Ph: (701) 306-4265 | April Marie Rohrer, FNP-C 3000 32nd Ave S, Fargo, ND 58103-6132 Ph: (701) 364-4354 |
News Archive
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
SARS-CoV-2 has spread around the world, passed across the borders of nations by travelers and cargo.
Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.
Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.
The U.S. Food and Drug Administration has announced the addition of a boxed warning to the label of Regranex Gel 0.01% (becaplermin) to address the increased risk of cancer mortality in patients who use 3 or more tubes of the product. Regranex is a topical cream indicated for the treatment of leg and foot ulcers that are not healing in diabetic patients.
› Verified 6 days ago
Wendy M Moore, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 901 28th St S, Fargo, ND 58103 Phone: 701-404-1100 Fax: 701-540-6498 | |
Mrs. Kayla L. Nelson, DNP, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 301 Np Ave N, Fargo, ND 58102 Phone: 701-271-3344 | |
Kyrie Marie Severson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4622 40th Ave S, Suite A, Fargo, ND 58104 Phone: 701-364-2909 Fax: 701-364-9822 | |
Sadie Marie Nelson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Sanford Broadway Clinic, 801 North Broadway, Fargo, ND 58102 Phone: 701-234-2000 | |
Jessica Smolen, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 321 8th Ave N, Fargo, ND 58102 Phone: 701-234-2525 | |
Mr. Nicholas Henry Frederiksen, APRN,CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Erin Marie Wilmes Reiniger, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4671 38th St S, Fargo, ND 58104 Phone: 701-404-5100 Fax: 701-499-1166 |